Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

2 Small-Cap Stocks Set to Shine in a Bull Market

Concept of Small Cap write on sticky notes isolated on Wooden Table.

Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities. These companies are nimble in nature, with some often delivering rapid revenue and earnings growth, which can translate into significant valuation increases.

The iShares Russell 2000 ETF (NYSE: IWM), representing the small-cap sector, has surged over 13% this quarter alone, highlighting the current investor appetite for these opportunities. With the market momentum carrying into year-end, some small-cap stocks trading under $5, especially those showing positive earnings growth, deserve closer attention.

2 Small-Cap Stocks With Positive EPS Growth Trading Under $5

CureVac: Extends Cash Runway Past 2028 With $583.4M on Balance Sheet

CureVac (NASDAQ: CVAC), a biopharmaceutical company specializing in mRNA-based medicines, is building an impressive pipeline that includes vaccines for infectious diseases and therapies for oncology. The company’s promising product candidates include second-generation COVID-19 vaccines and seasonal flu treatments developed in collaboration with GSK. CureVac also has active trials for mRNA-based therapies targeting melanoma and other cancers.

Although the stock has struggled in 2024, down 24% YTD, CureVac’s Q3 results suggest brighter days ahead. It reported a 3000% year-over-year revenue increase to $520 million, fueled by a $423.5 million upfront payment from its revised partnership with GSK. The collaboration extends CureVac’s cash runway beyond 2028, with $583.4 million now on its balance sheet. Furthermore, the company achieved an EPS of $1.54, easily beating estimates.

CureVac’s valuation looks appealing, trading at a P/E ratio of 5.91 with a current ratio of 6.2, signifying strong liquidity. Analysts have set a price target of $10, representing a potential upside of over 200%. However, recent data shows mixed institutional sentiment: Point72 Asset Management reduced its holdings by 67.8% last quarter. While this raises questions, it also provides an entry point for those confident in CureVac’s long-term potential.

HeartCore Expands Recurring Revenue With Multi-Year Licensing Agreements

HeartCore Enterprises (NASDAQ: HTCR), a Japan-based software development company, focuses on enhancing customer experience through its suite of SaaS solutions. Its offerings include marketing automation, content management systems (CMS), and digital transformation tools, such as robotic process automation. HeartCore has also entered multi-year licensing agreements, signaling a shift to more predictable recurring revenue streams.

Unlike CureVac, HeartCore has seen its stock soar in 2024, up 150% YTD, with nearly 140% of that gain occurring this quarter. This rally is supported by its Q3 results, where HeartCore exceeded both revenue and earnings expectations. The company reported $0.53 EPS, beating consensus estimates by over 50%, on $17.85 million in revenue. Recent strategic initiatives, including a new “Health Check” consultation program, aim to deepen customer relationships and unlock further sales growth.

HeartCore has a client retention rate of 25.9% exceeding 10 years, and the company projects a 12% increase in sales from its CMS customers in FY 2025. Despite its strong performance and forward momentum, HeartCore remains under the radar, with minimal analyst coverage and low institutional ownership. Its market capitalization of just $33 million makes it a speculative play but also an attractive opportunity for early investors willing to embrace higher risk and conduct further due diligence on the company and its sector.

Investors looking to capitalize on the current bull market in small caps should weigh the risks and rewards carefully. While these stocks offer compelling growth narratives, their small market capitalizations, and high volatility require a disciplined approach. For those willing to take a closer look, these two stocks may present unique opportunities in an otherwise speculative market.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.